A once-daily GLP-1 receptor agonist decreased events of level 2 and level 3 hypoglycemia for adults after Roux-en-Y gastric bypass, according to topline results from a phase 3 trial.
Avexitide (Amylyx Pharmaceuticals) is a first-in-class GLP-1 that is being assessed to treat post-bariatric hypoglycemia, a condition that is thought to be caused by exaggerated GLP-1 response. According to a press release from Amylyx Pharmaceuticals, there are no currently approved therapies for post-bariatric hypoglycemia.
In the phase 3 LUCIDITY trial, researchers enrolled 78 adults who underwent gastric bypass

A telehealth-based smoking cessation program significantly improved quit rates among patients with cancer treated at community practices.
A randomized trial showed patients who received the virtual intervention, which also included no-cost medication, achieved double the abstinence rate at 6 months compared with those who were referred to the NCI quitline.
“Helping patients stop smoking after a cancer diagnosis is feasible and impactful, and it can be readily embedded into community oncology care,” Jamie S. Ostroff, PhD, chief of behavioral sciences service and director of the tobacco treatment

The American College of Cardiology issued an updated expert consensus decision pathway outlining best practices for the diagnosis and management of heart failure with preserved ejection fraction.
As Healio previously reported, the prior iteration of the decision pathway published in 2023 emphasized the need for a multidisciplinary approach for HFpEF diagnosis and was based on earlier data on the benefits of SGLT2 inhibitors in this patient population.
The updated document, published in the Journal of the American College of Cardiology, provides information on best practices for ruling out HFpEF

Click here to read the Healio Exclusive, “Interventional glaucoma takes center stage as adoption accelerates.”
It is estimated that 4.22 million Americans have glaucoma.
Glaucoma is age related, with a rate of 2.56% in people older than age 40 years and 1.62% in people aged 18 years and older. In America, primary open-angle glaucoma (POAG) is the most common diagnosis, and a Black adult is at higher risk. Two large challenges in managing glaucoma are undiagnosed disease and poor compliance with eye drop medical treatment.
It is estimated that only 50% of Americans with glaucoma have been

Intensive blood pressure-lowering strategies reduced recurrent stroke as well as major cardiovascular events in patients after spontaneous intracerebral hemorrhage, according to a meta-analysis published in The Lancet Neurology.
There were approximately 16 fewer recurrent strokes among each 1,000 patients who received treatment within 1 year, and absolute reductions increased as follow-up progressed, Craig Anderson, PhD, senior professional fellow at The George Institute for Global Health, and colleagues wrote.
Overall, the meta-analysis found intensive blood pressure-lowering treatment to

Preliminary results on computerized gait analysis interpretation and treatment showed stronger physician reliability across multiple institutions than previously reported.
“Gait analysis is a key component in assessing how to optimally treat children with walking disorders,” Robert M. Kay, MD, division chief of orthopedic surgery and medical director of the Jackie and Gene Autry Orthopedic Center at Children’s Hospital Los Angeles, told Healio about results presented at the Gait and Clinical Movement Analysis Society Annual Conference. “Motion analysis has been shown to enhance our treatment

Adults with type 1 diabetes receiving tirzepatide off-label had a similar rate of new-onset diabetic retinopathy compared with controls not using the drug, according to a chart review published in Diabetes Technology & Therapeutics.
Satish K. Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, said there has been interest in assessing the impact incretin-based medications have on eye disease ever since the SUSTAIN-6 trial found semaglutide (Ozempic, Novo Nordisk) was associated with increased risk for

GLP-1 receptor agonists are among the most innovative and transformative medications to come on the market in my professional lifetime.
The potential health benefits include weight loss, blood sugar control (for diabetic and nondiabetic patients alike), reduced ruminations about food, decreased alcohol cravings and improved sleep apnea.
However, these medications are not a one-stop solution. There should be a concomitant commitment to lifestyle and behavioral changes. I spoke with Lucy McBride, MD, a primary care physician in Washington, DC, about where GLP-1s are playing a role in her

A recent study published in Allergy found larger improvements in long-term patient outcomes among those who achieved remission vs. desensitization of peanut allergy after ending peanut oral immunotherapy.
In the follow-on study of a randomized controlled trial (PPOIT-003LT), Mimi Tang, MBBS, PhD, FRACP, FRCPA, FAAAAI, director of the Allergy Translation Centre and group leader of allergy immunology at Murdoch Children’s Research Institute, and colleagues assessed 129 patients who completed 18 months of high-dose (2,000 mg) probiotic peanut OIT, standalone high-dose peanut OIT or placebo to

New B-cell targeting agents could potentially usher in a “new era” of Sjögren’s disease treatment, with the first FDA approval expected within the next year, according to a presenter at the AWIR annual conference.
“I want to talk about what is coming down the pipeline and what we have to look forward to,” said Rachael Gordon, MD, PhD, assistant professor of medicine at the University of Pittsburgh Medical Center and director of the UPMC Sjögren’s Center. “There are several agents that have met phase 2 and phase 3 clinical trial endpoints. Many of these